Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 29, 2004 W.D. Crotty	OraSure Not That Sure Its oral-fluid HIV test is a breakthrough, but the stock isn't cheap.
Chemistry World July 3, 2012 Andrew Turley	US approves HIV home test kit The 'OraQuick' kit from US diagnostics firm OraSure, is already in use by clinics, but until now the company has not been allowed to market it for home use.
The Motley Fool November 27, 2009 Brian Orelli	A Mostly Meaningless FDA Approval After an accelerated approval, the positive effects of a full approval are minimal for Johnson & Johnson's drug, Intelence.
The Motley Fool September 22, 2006 Brian Lawler	Healthy Rec for OraSure The CDC recommends that HIV testing become routine for everyone aged 13-64. Investors, this is good news for medical diagnostic companies.
The Motley Fool December 31, 2003 Alyce Lomax	Nothing Decisive About Encysive Analyst initiation boosts the stock during the slow holiday week.
American Journal of Nursing March 2010 Bradley-Springer et al.	Every Nurse Is an HIV Nurse The evolution of HIV infection into a chronic disease has implications across all clinical care settings. Every nurse should be knowledgeable about the disease in order to provide high-quality care to people with or at risk for HIV.
American Family Physician July 15, 2004 Joel E. Gallant	HIV Counseling, Testing, and Referral By the year 2005, the CDC seeks to achieve the following: reduce annual new HIV infections from the current estimated 40,000 cases to 20,000 cases through the use of interventions such as counseling, HIV testing, and referral
The Motley Fool June 21, 2007 Brian Lawler	Pfizer Gets Held Up The FDA issues an approvable letter for its novel HIV compound. Investors, take note.
The Motley Fool May 15, 2007 Mike Havrilla	Risky Bet OraSure Thing? The company strides forward to offer quick, less invasive methods of testing for disease and drugs. Investors, take note.
The Motley Fool September 25, 2007 Brian Orelli	Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note.
Chemistry World July 17, 2012 Andrew Turley	First HIV drug approved as prevention US regulators have for the first time approved a drug to be used to prevent HIV infection -- as opposed to treating it.
Chemistry World March 1, 2012 Simon Hadlington	Quicklime provides a hot way for rapid HIV detection US researchers have developed a rapid testing kit for HIV, which uses nothing more sophisticated than quicklime to power it.
The Motley Fool July 16, 2011 Melly Alazraki	HIV Studies May Not Mean Much to Gilead Studies find Gilead drugs can help prevent HIV infections, but that may not help sales.
The Motley Fool May 2, 2007 Brian Lawler	Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note.
The Motley Fool October 16, 2007 Brian Orelli	Not a Blockbuster -- Yet Merck gains marketing approval for its newest HIV drug. Investors, take note.
The Motley Fool September 7, 2007 Brian Orelli	Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells.
BusinessWeek April 1, 2010 Bennett & Randall	Will an AIDS Pill a Day Keep the Virus Away? Drugmaker Gilead is betting the one-pill PrEP treatment will slow the virus' spread - as are some of the world's top health agencies and philanthropists.
American Family Physician January 1, 2001	HIV Infection and Pregnancy-Protecting Your Baby and Yourself Why should I be tested for HIV if I am pregnant?... How do babies get HIV?... What can I do to keep my baby from getting HIV?... What antiretroviral medicines should I be taking?... Should I have an elective cesarean section?...
AskMen.com Dave Golokhov	Truvada With more and more studies finding successful AIDS prevention, it looks like we're getting closer to finding a cure.
Chemistry World April 27, 2007 Ned Stafford	New HIV Blocker Prepares for Trials Scientists who isolated a natural component of human blood that defends against the HIV-1 virus are now moving quickly to test their ideas clinically in the hope of bringing a new class of HIV-blockers based on peptide therapeutics to market.
Nursing January 2011 Carl A. Kirton	HIV: The Changing Epidemic Since its emergence in the early 1980s, HIV infection in the United States has evolved from an acute debilitating condition to a chronic, treatable illness.
The Motley Fool January 21, 2010 Brian Orelli	Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really?
The Motley Fool July 21, 2006 Brian Lawler	Gilead's Acquisitive Mood Trading at around 28 times 2006 EPS estimates, and with 40% growth expected for its HIV franchise, Gilead offers tempting value -- assuming it makes smart use of that cash sitting on the balance sheet.
The Motley Fool December 31, 2007 Brian Lawler	Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year.
The Motley Fool July 13, 2004 Charly Travers	With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market.
The Motley Fool April 8, 2004 Charly Travers	Indevus' Big Score (Maybe) A small biotech company lands a potentially rich deal.
The Motley Fool May 24, 2011 Brian Orelli	J&J Approved, but Needs Help From a Friend The HIV combo product is the key.
Chemistry World August 4, 2008 Pete Mitchell	Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate.
Pharmaceutical Executive December 1, 2005 Alana Klein	Thought Leader: A Q&A with Graham Allaway While researchers continue to hunt for new AIDS drugs, Graham Allaway, chief operating officer of Panacos Pharmaceuticals, is focusing on developing a treatment for patients failing therapy due to resistance.
The Motley Fool February 23, 2010 Brian Orelli	The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston.
BusinessWeek October 20, 2003 Gene G. Marcial	How Immune Response Targets AIDS Immune Response's Remune is aimed at slowing the advance of HIV and delaying the need for antiretroviral drugs, which have toxic effects. A look at the company's situation and its stock.
American Family Physician May 15, 2002	HIV in Women What are HIV and AIDS?... How do women become infected with HIV?... Is HIV infection different in women and men?... What precautions can be taken to avoid getting HIV during sex?... What should I do if I think I may be infected?...
The Motley Fool July 17, 2009 Brian Orelli	Have a Cocktail Two virus killers are better than one. The latest two to hook up are Gilead Sciences and Johnson & Johnson.
The Motley Fool May 4, 2006 Brian Gorman	Trinity's Breakneck Expansion The diversified manufacturer remains on course for continued solid earnings growth. But as expansion continues, balance sheet health should be considered another metric of the company's success. Investors, take note.
The Motley Fool June 26, 2008 Brian Lawler	Ardea Takes the More Exciting Route Ardea Bioscicences announces phase 2a data for its lead anti-HIV drug that is good enough to encourage further testing.
Chemistry World June 13, 2012 Elinor Hughes	Paper and plastic HIV test A DNA test to detect HIV in infants in resource-poor countries is a step closer, thanks to a technique to amplify DNA samples developed by US scientists.
Chemistry World April 1, 2011 Erica Wise	DNA detection for rapid HIV diagnosis The diagnosis of HIV in developing countries could be quicker using a low cost device developed by US scientists.
Pharmaceutical Executive March 1, 2012 Ron Cohen	FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership.
Chemistry World September 24, 2015	A new hope in HIV prevention New microbicide products could turn the tide against Aids for those who need it most: women in sub-Saharan Africa. Dinsa Sachan reports.
Nursing May 2009 Davenport & Myers	How to Protect Yourself After Body Fluid Exposure Here's how you can minimize the risk of disease transmission if you or a coworker is accidentally exposed to blood or another potentially infectious body fluid.
The Motley Fool July 19, 2010 Brian Orelli	Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so.
Fast Company March 2015 J.J. McCorvey	How Drug Company Gilead Outpaces Its Competitors -- And Common Diseases Over the past few years, Gilead has ushered through four effective new treatments for HIV alone.
The Motley Fool February 18, 2010 Brian Orelli	Gilead Shareholders Are Whistling a Happy Tune Full data from the company's HIV quad pill show no major issues.
American Journal of Nursing March 2010 David E. Vance	Aging with HIV: Clinical Considerations for an Emerging Population Since the advent of highly active antiretroviral therapy, HIV infection has become a chronic, albeit life-threatening, condition that can be managed; therefore, more and more people are growing older with HIV.
Chemistry World September 3, 2009 Sarah Houlton	New HIV vaccine hope A team of scientists in the US has discovered two new antibodies that could lead to an HIV vaccine.
Chemistry World February 9, 2007 Victoria Gill	Africa's First Large-Scale HIV Vaccine Trial The first large-scale clinical trial of an HIV vaccine will involve around 3000 participants in five selected sites in South Africa. It will compare the effectiveness of the vaccine at reducing HIV infection compared to a placebo.
BusinessWeek April 25, 2005 Sarah Lacy	BW50: Gilead's Big Growth Spurt The small biotech rivals the majors in HIV drugs. Now it must expand beyond its niche
The Motley Fool August 24, 2005 Tarek Sultani	Panacos Gives HIV Reason to Panic Panacos' new anti-retroviral PA-457 has huge implications for the company's future. The stock price soared 46% Monday, closing at $10.30. While this surge may seem enormous, it's only the tip of the iceberg if this drug proves as successful as these trials indicate.
American Family Physician July 15, 2004	HIV Infection - How to Lower Your Risk A consumer-oriented brochure discussing the many ways to lower the risk of getting human immunodeficiency virus (HIV) infection and where to go for help.
The Motley Fool June 13, 2005 Brian Gorman	Trinity Almost On Track Earnings continue to improve, even as the railcar maker's balance sheet has suffered. Investors should keep a close watch to make sure the firm doesn't overextend itself.